Something interesting happens when you poll people who treat HIV -- and people who have HIV -- about whether they'd prefer a treatment option that consists of a periodic injection or infusion in place of the pill or pills that they take every day.
Medical marijuana is now officially available in New York, the city with by far the largest number of people living with HIV/AIDS in the country. Reporting on the first dispensary in Manhattan, the aptly named Julie Weed (yes! her real name!) writes:
Earlier this week, JAMA Internal Medicine published a study entitled, "Level of Computer Use in Clinical Encounters Associated with Patient Satisfaction".
A more descriptive title would have been "More Computer Use in Clinical Encounters Associated with Reduced Patient Satisfaction", as here's the take home point:
Some quick ID/HIV gratitude items for 2015, done rapidly as we're hosting a big meal later today.
I wonder what that might be.
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
In this article, South African HIV prevention activist and member of the Vaccine Advocacy Resource Group -- a small, global group of advocates specifically focused on the HIV vaccine research field -- Tian Johnson reflects on his participation in the recent HVTN Conference in Cape Town, his hope for a vaccine and the necessity of advocates' involvement in the search. This first appeared in NGO Pulse.
I almost wrote "raging controversy" -- but the adjective "raging" doesn't really fit the sort of people who specialize in Infection Control, who are some of the most measured, data-driven, and methodical individuals in all of medicine. You know the stereotype of the brash, volatile, and cowboy surgeon, the person that everyone tiptoes around?
After reporting my choice for the most important HIV study at ICAAC, I received this email from a colleague:
In the newspaper today -- and yes, we still do get it delivered (some habits die hard) -- is this headline: "Millions More Need H.I.V. Treatment, W.H.O. Says"
It's true -- these updated guidelines say that all should be treated soon after diagnosis, regardless of CD4 cell count or whether they have symptoms.
The big ID story the past couple of weeks is that the price of pyrimethamine -- a drug that's been available generically for decades -- went from $13.50 to $750 for one pill after the exclusive rights to the drug were purchased by Turing Pharmaceuticals.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.